Quid - as an investor, I think about maximizing gains, long-term. The dilution unpleasantries will continue, however if leadership is highly confident in our near-midterm progress, an offering can be extended at a higher PPS at a later date for more $; hence displaying strength.
The bird in the hand mentality is shortsighted if leadership is highly confident in the product, physician leaders involved and milestone execution. This affects you as an investor - higher o/s count, the higher the potential RS (Ex. 20-1 v 10-1), which potentially increases exposure and disallows you from maximizing the full potential of your investment. Help me understand how anyone with experience in investing or business could think otherwise.